Not available
Quote | Neuralstem Inc. (NASDAQ:CUR)
Last: | $ |
---|---|
Change Percent: | -2.27% |
Open: | $1.24 |
Close: | $1.29 |
High: | $1.29 |
Low: | $1.20 |
Volume: | 78,429 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Neuralstem Inc. (NASDAQ:CUR)
2024-07-22 05:37:00 ET Read the full article on Seeking Alpha For further details see: Commodity Roundup: Gold holds steady, oil reverses early gains amid Gaza ceasefire hopes
2024-07-20 07:30:00 ET Summary Central banks buying gold, pushing prices higher. What could push gold prices higher from current highs. Why gold-related ETFs may potentially catch up to the price of bullion. ... Read the full article on Seeking Alpha ...
Message Board Posts | Neuralstem Inc. (NASDAQ:CUR)
Subject | By | Source | When |
---|---|---|---|
$SNCA~could be crazy huge,got @1.65 pps | ALERTS100%to10000%GAIN | investorshub | 04/26/2021 1:36:03 PM |
Yes merger in play here loading up $$$$ | INFINITI | investorshub | 04/05/2021 12:52:06 PM |
$SNCA is screaming for the top as investors | AlphaStockNews | investorshub | 04/05/2021 10:55:59 AM |
Whos the idiots that are selling this low | INFINITI | investorshub | 03/31/2021 11:42:44 PM |
Filing of Certain Prospectuses and Communications in Connection | INFINITI | investorshub | 03/30/2021 11:09:04 AM |
News, Short Squeeze, Breakout and More Instantly...
RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was dosed at the University of California Irvine. The trial will be conducted at 10-15 clinica...
GERMANTOWN, Md. , Sept. 2, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today provided the following letter from Dr. Ken Carter , the Company's Executive Chairm...
GERMANTOWN, Md. , May 27, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced the closing of its previously announced $5 million registered...